ORTEXORTEX News
Tracking TRU? Get live short interest, options flow, and signals on ORTEX.Sign up free →
TR
Trader NoteTRU

TransUnion Surges 16% as Short Sellers and Analysts Diverge Before Thursday's Print

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 3 min readdata as of 21 Oct 2026, 22:30

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

TransUnion, the consumer credit data company, reports Q3 earnings on October 23 against a backdrop that has shifted fast: the stock is up 16% this week, short interest is at its highest level in over a year, and analysts have spent October cutting price targets while largely keeping positive ratings.

The short position is the most striking feature. Short interest has grown 37% over the past month to reach 7.3% of the free float, the largest short book in the recent data window. The ORTEX short score has risen steadily from 49.5 on October 8 to 58.8 on October 20, a meaningful directional shift over just two weeks. Yet the borrow market is not under stress. The cost to borrow has actually eased, down 16% on the week to 0.45%, and availability is wide at 241%, meaning roughly two-and-a-half shares remain available to borrow for every share currently shorted. Short sellers are adding exposure into a stock that is rallying hard, but the lending market is not showing any squeeze mechanics.

Options have flipped in the opposite direction. The put/call ratio fell to 0.86 on Tuesday, well below its 20-day average of 1.10. A week ago it was at the 52-week high of 2.24. That swing, from maximum defensiveness to a reading below the recent norm in under five trading days, tracks almost exactly with the 16% price move and suggests options traders repositioned aggressively into calls as the stock bounced. The two signals are now pointing in different directions: short sellers adding, options traders buying upside.

Analyst sentiment has been moving consistently lower, though not enough to shift the overall stance. Morgan Stanley cut its target from $106 to $97 earlier this month while keeping an Overweight rating. Goldman Sachs trimmed twice in three weeks, from $89 to $77 to $68, but also held at Neutral. RBC Capital and Needham both lowered targets into the $85 to $92 range. UBS went the other way on Tuesday, raising its target from $75 to $83 after the stock recovered, though it stayed at Neutral. The mean price target across the Street is $89.19, representing roughly 14% above Tuesday's close of $78.23. The valuation tells a similar story: the P/E has expanded 2.2 turns over the past week to 14.7x, and EV/EBITDA has moved up half a turn, but both remain well below where many of these same analysts set their targets earlier in the year. Factor scores are weak on earnings momentum, with the 30-day EPS momentum rank at the 20th percentile and the 90-day rank at the 35th.

The bear case rests on TransUnion's mortgage and consumer lending exposure at a time when the macro picture is uncertain, and on questions about VantageScore adoption. The bull case points to international positions in high-growth markets and new revenue lines in tenant screening and income verification. Equifax, the most closely correlated peer, gained 11% on Tuesday alone and 18% over the past week, fractionally outpacing TransUnion's own move, which suggests the credit data sector broadly caught a bid rather than TransUnion seeing idiosyncratic buying. Experian and Verisk were more modest, up 7% and 8% respectively on the week.

The institutional register has been active on the buy side over a longer horizon. Dodge & Cox, the largest holder at 12.6% of shares, added over 8 million shares as of the June quarter-end. Citadel added 1.2 million shares in the same period. Wellington trimmed its 13G stake from 5.6% to 3.4%, below the threshold at which further disclosures are required, so its current position is unknown. All 13D/G stakes are as-last-disclosed and subject to change without notice.

Recent insider transactions are worth noting for context rather than as a directional signal. All recent sales were executed under pre-arranged 10b5-1 plans, which reduces their informational value. The one outlier is a grant of 123,834 shares to the EVP of Strategy and Corporate Development on October 1, a compensation event rather than a market transaction.

The numbers Thursday's report needs to answer are the ones the Street has been cutting targets over: how much pressure the mortgage environment is applying to US financial services revenue, and whether international growth is accelerating enough to offset it. With the stock up 16% in a week and short interest at its highest level in a year, both sides of that trade are live going into the print.

Stocks in this article

See the live data behind this article on ORTEX.

Open TRU on ORTEX →

How this article was generated

Generated
21 Oct 2026, 22:31
Data as of
21 Oct 2026, 22:30
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.